Poseida Therapeutics, Inc. (PSTX)


+0.09 (+4.07%)
Symbol PSTX
Price $2.175
Beta 0.050
Volume Avg. 0.94M
Market Cap 206.862M
Shares () -
52 Week Range 1.54-8.82
1y Target Est -
DCF Unlevered PSTX DCF ->
DCF Levered PSTX LDCF ->
ROE -17.55% Sell
ROA -10.87% Sell
Operating Margin -
Debt / Equity 64.36% Buy
P/E -43.50 Strong Sell
P/B 1.40 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest PSTX news

Mr. Mark J. Gergen J.D.
NASDAQ Global Select

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.